View Financial HealthStageZero Life Sciences 配当と自社株買い配当金 基準チェック /06StageZero Life Sciences配当金を支払った記録がありません。主要情報n/a配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • May 08StageZero Life Sciences Ltd. announced that it expects to receive CAD 2 million in fundingStageZero Life Sciences Ltd. announced a private placement transaction of of either, or a combination of: (i) up to CAD 2,000,000 of non-convertible notes bearing an interest rate of between 12 % to 14 per % per annum; or a convertible debt offering up to CAD 800,000 of units; each unit consisting of CAD 1,000 principal amount of unsecured convertible debentures bearing an interest rate of 8 % per annum, and 12,500 common share purchase warrants, provided that the aggregate gross proceeds from the debt offering and the convertible debt offering would not exceed CAD 2,000,000 on a combined basis on May 7, 2025. Each warrant is exercisable for one common share of the issuer. The principal amount of the convertible debentures may be converted by the holders into common shares at a floor conversion price to be determined based on the market price of the issuer's common shares on the Toronto Stock Exchange following recommencement of trading of the issuer's common shares on TSX (as required by applicable TSX policies). Each warrant shall be exercisable to purchase a common share at an exercise price that will be three cents higher than the market price for a period of 18 months. The proposed financing is subject to the approval of the TSX.お知らせ • Apr 03StageZero Life Sciences Ltd. to Report Q4, 2023 Results on May 31, 2024StageZero Life Sciences Ltd. announced that they will report Q4, 2023 results on May 31, 2024お知らせ • Nov 08StageZero Life Sciences, Ltd. Clinical Business Introduces Fourth Pillar to Cancer OfferingsStageZero Life Sciences Ltd. announced that its Clinical Business, Care Oncology, has added the fourth of a series of new program offerings. Pinky Jimenez-Agrawal, with WellnessScript, will provide mental health support specifically for cancer patients at twice-monthly clinics. The first clinic is Thursday November 9, 2023 and is open to patients globally. Screening to find cancer early is the first pillar (AristotleTM); adjunctive treatment with the Care Oncology Protocol is the second; nutritional guidance tailored to the type and stage of the cancer is the third pillar and mental health support is the fourth pillar. The Company believes that these additional offerings present an excellent entry point for cancer patients to be introduced to the full Care Oncology program. One in three patients with cancer have challenges with mental health: up to 25% of cancer survivors suffer from depression and up to 45% with anxiety. Supporting individuals on their journey towards recovery as well as offering help to terminally ill patients and their families as they prepare for death, is a key aspect of her work. She runs bimonthly drop-in sessions, and provides psychological support on a 1:1 basis, for the members of a leukaemia charity. As a volunteer therapist for Cruse Bereavement Care, she provides counselling to children and young adults. She's an ACT practitioner and a DBT informed therapist. She uses a combination of therapies and mindfulness-based interventions. Her work helps individuals build on their strengths by helping them learn new skills, expand from their own experience and teach strategies to enable them to cope with their issues and develop better well-being habits. The program will be offered virtually, twice a month. The program is open to anyone, not just Care Oncology patients and with times to allow global participation. Interested individuals can sign up at [1]. Participants will pay directly for each session. Care Oncology offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Care Oncology has been treating cancer patients since 2013 using patented COC Protocol™?. It is an individualized therapeutic approach which seeks to simultaneously target multiple metabolic cancer pathways and is intended for adjunctive administration alongside standard-of-care cancer therapy. The aim is to restrict cancer cell energy supply and use. In addition to the COC Protocol, Care Oncology offers the AVRT preventative program. All of the Care Oncology programs are managed by a multi-disciplinary team that is overseen by Oncologists and includes Nurse practitioners and Metabolic Specialists.お知らせ • Oct 21Stagezero Life Sciences, Ltd. Clinical Business Introduces Third Pillar to Cancer OfferingsStageZero Life Sciences Ltd. announced that its Clinical Business Care Oncology, has added the first of a series of new program offerings. The Source Functional Nutrition group will provide educational sessions, live cooking lessons, bi-weekly drop in Cafe's, 1:1 consultation as well as a library of recipes and videos. The program initiatives Friday, October 27th. Screening to find cancer early is the first pillar (AristotleTM); adjunctive treatment with the CareOncology Protocol is the second; nutritional guidance tailored to the type and stage of the cancer is the third pillar. "25-80% of cancer patients, depending on their age and the type and stage of thecancer, suffer from mal nutrition. This problem has become much more acute since the COVID pandemic as treatment options were delayed and access curtailed. Chemotherapy patients, especially, rely on Oncology Nutrition to help with physical strength and assistance during treatment. Nutritional screening and evaluation, as well as detailed nutritional guidance, are essential to assist with a good outcome" said James Howard-Tripp, Chairman and CEO of StageZero Life Sciences. The Source Functional Nutritional offering provides cancer specific nutritional guidance with group information sessions, cooking lessons and one on one sessions. Diet is key to supporting a patient's ability to manage treatment and retain strength. dietary guidance can differ between cancer type and stage of treatment. TheSource program will show participants how to navigate this with concrete tools and recipes. Care Oncology offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Care Oncology has been treating cancer patients since 2013 using patented COC Protocol™?. It is an individualized therapeutic approach which seeks to simultaneously target multiple metabolic cancer pathways and is intended for adjunctive administration alongside standard-of-care cancer therapy. The aim is to restrict cancer cell energy supply and use. In addition to the COC Protocol, Care Oncology offers the AVRT program. All of the Care Oncology programs are managed by a multi-disciplinary team that is overseen by an Oncologist and includes Nurse Practitioners and Metabolic Specialists. Care Oncology Clinics also offers AVRT a Physician-Led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Aristotle®? is processed at the Company's clinical laboratory, StageZero Life Sciences Inc., a CAP accredited and CLIA certified high-complex cancer.お知らせ • May 16StageZero Life Sciences Ltd. to Report Q1, 2023 Results on May 15, 2023StageZero Life Sciences Ltd. announced that they will report Q1, 2023 results on May 15, 2023決済の安定と成長配当データの取得安定した配当: SZLS.Fの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: SZLS.Fの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場StageZero Life Sciences 配当利回り対市場SZLS.F 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (SZLS.F)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Biotechs)2.4%アナリスト予想 (SZLS.F) (最長3年)n/a注目すべき配当: SZLS.Fは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: SZLS.Fは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: SZLS.Fの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: SZLS.Fが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/28 20:51終値2026/03/24 00:00収益2023/09/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋StageZero Life Sciences Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Douglas LoeCantor Fitzgerald Canada CorporationChris ThompsoneResearch CorporationClaude CamiréParadigm Capital, Inc.
お知らせ • May 08StageZero Life Sciences Ltd. announced that it expects to receive CAD 2 million in fundingStageZero Life Sciences Ltd. announced a private placement transaction of of either, or a combination of: (i) up to CAD 2,000,000 of non-convertible notes bearing an interest rate of between 12 % to 14 per % per annum; or a convertible debt offering up to CAD 800,000 of units; each unit consisting of CAD 1,000 principal amount of unsecured convertible debentures bearing an interest rate of 8 % per annum, and 12,500 common share purchase warrants, provided that the aggregate gross proceeds from the debt offering and the convertible debt offering would not exceed CAD 2,000,000 on a combined basis on May 7, 2025. Each warrant is exercisable for one common share of the issuer. The principal amount of the convertible debentures may be converted by the holders into common shares at a floor conversion price to be determined based on the market price of the issuer's common shares on the Toronto Stock Exchange following recommencement of trading of the issuer's common shares on TSX (as required by applicable TSX policies). Each warrant shall be exercisable to purchase a common share at an exercise price that will be three cents higher than the market price for a period of 18 months. The proposed financing is subject to the approval of the TSX.
お知らせ • Apr 03StageZero Life Sciences Ltd. to Report Q4, 2023 Results on May 31, 2024StageZero Life Sciences Ltd. announced that they will report Q4, 2023 results on May 31, 2024
お知らせ • Nov 08StageZero Life Sciences, Ltd. Clinical Business Introduces Fourth Pillar to Cancer OfferingsStageZero Life Sciences Ltd. announced that its Clinical Business, Care Oncology, has added the fourth of a series of new program offerings. Pinky Jimenez-Agrawal, with WellnessScript, will provide mental health support specifically for cancer patients at twice-monthly clinics. The first clinic is Thursday November 9, 2023 and is open to patients globally. Screening to find cancer early is the first pillar (AristotleTM); adjunctive treatment with the Care Oncology Protocol is the second; nutritional guidance tailored to the type and stage of the cancer is the third pillar and mental health support is the fourth pillar. The Company believes that these additional offerings present an excellent entry point for cancer patients to be introduced to the full Care Oncology program. One in three patients with cancer have challenges with mental health: up to 25% of cancer survivors suffer from depression and up to 45% with anxiety. Supporting individuals on their journey towards recovery as well as offering help to terminally ill patients and their families as they prepare for death, is a key aspect of her work. She runs bimonthly drop-in sessions, and provides psychological support on a 1:1 basis, for the members of a leukaemia charity. As a volunteer therapist for Cruse Bereavement Care, she provides counselling to children and young adults. She's an ACT practitioner and a DBT informed therapist. She uses a combination of therapies and mindfulness-based interventions. Her work helps individuals build on their strengths by helping them learn new skills, expand from their own experience and teach strategies to enable them to cope with their issues and develop better well-being habits. The program will be offered virtually, twice a month. The program is open to anyone, not just Care Oncology patients and with times to allow global participation. Interested individuals can sign up at [1]. Participants will pay directly for each session. Care Oncology offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Care Oncology has been treating cancer patients since 2013 using patented COC Protocol™?. It is an individualized therapeutic approach which seeks to simultaneously target multiple metabolic cancer pathways and is intended for adjunctive administration alongside standard-of-care cancer therapy. The aim is to restrict cancer cell energy supply and use. In addition to the COC Protocol, Care Oncology offers the AVRT preventative program. All of the Care Oncology programs are managed by a multi-disciplinary team that is overseen by Oncologists and includes Nurse practitioners and Metabolic Specialists.
お知らせ • Oct 21Stagezero Life Sciences, Ltd. Clinical Business Introduces Third Pillar to Cancer OfferingsStageZero Life Sciences Ltd. announced that its Clinical Business Care Oncology, has added the first of a series of new program offerings. The Source Functional Nutrition group will provide educational sessions, live cooking lessons, bi-weekly drop in Cafe's, 1:1 consultation as well as a library of recipes and videos. The program initiatives Friday, October 27th. Screening to find cancer early is the first pillar (AristotleTM); adjunctive treatment with the CareOncology Protocol is the second; nutritional guidance tailored to the type and stage of the cancer is the third pillar. "25-80% of cancer patients, depending on their age and the type and stage of thecancer, suffer from mal nutrition. This problem has become much more acute since the COVID pandemic as treatment options were delayed and access curtailed. Chemotherapy patients, especially, rely on Oncology Nutrition to help with physical strength and assistance during treatment. Nutritional screening and evaluation, as well as detailed nutritional guidance, are essential to assist with a good outcome" said James Howard-Tripp, Chairman and CEO of StageZero Life Sciences. The Source Functional Nutritional offering provides cancer specific nutritional guidance with group information sessions, cooking lessons and one on one sessions. Diet is key to supporting a patient's ability to manage treatment and retain strength. dietary guidance can differ between cancer type and stage of treatment. TheSource program will show participants how to navigate this with concrete tools and recipes. Care Oncology offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Care Oncology has been treating cancer patients since 2013 using patented COC Protocol™?. It is an individualized therapeutic approach which seeks to simultaneously target multiple metabolic cancer pathways and is intended for adjunctive administration alongside standard-of-care cancer therapy. The aim is to restrict cancer cell energy supply and use. In addition to the COC Protocol, Care Oncology offers the AVRT program. All of the Care Oncology programs are managed by a multi-disciplinary team that is overseen by an Oncologist and includes Nurse Practitioners and Metabolic Specialists. Care Oncology Clinics also offers AVRT a Physician-Led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Aristotle®? is processed at the Company's clinical laboratory, StageZero Life Sciences Inc., a CAP accredited and CLIA certified high-complex cancer.
お知らせ • May 16StageZero Life Sciences Ltd. to Report Q1, 2023 Results on May 15, 2023StageZero Life Sciences Ltd. announced that they will report Q1, 2023 results on May 15, 2023